# US 2016/0250265 A1 · Non-replicating probiotic micro-organisms protect against upper respiratory tract infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250265 A1
- Document ID: US20160250265A1
- Status: Published application
- Kind: A1
- Application number: 15/151,762
- Filed: 2016-05-11
- Published: 2016-09-01
- Earliest claimed: 2010-11-11
- Assignees: Nestec S.A.
- Applicants: Nestec S.A.
- Inventors: Valerie Petit; Clara Lucia Garcia-Rodenas; Monique Julita; Annick Mercenier; Guenolee Prioult; Sophie Nutten
- Web page: https://patentgrep.com/patent/US20160250265A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/742: Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/745: Bifidobacteria
- A61P 11/00: Drugs for disorders of the respiratory system
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/36: Adaptation or attenuation of cells
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention can help parents to protect their children from such upper respiratory tract infections.

## Claims

### Claim 1

A method for treatment of an upper respiratory tract infection, the method comprising:
administering to an individual in need of same a composition comprising non-replicating probiotic micro-organisms that have been rendered non-replicating by a heat-treatment at 120-140° C. for about 1-120 seconds, the non-replicating probiotic micro-organisms selected from the group consisting of Bifidobacteria, Lactobacilli, Propionibacteria, and combinations thereof.

### Claim 2 (depends on 1)

The method in accordance with claim 1, wherein the individual is a child.

### Claim 3 (depends on 2)

The method in accordance with claim 2, wherein the composition strengthens the child's ability to fight the upper respiratory tract infection.

### Claim 4 (depends on 1)

The method in accordance with claim 1, wherein the upper respiratory tract infection is selected from the group consisting of rhinitis, rhinosinusitis, nasopharyngitis, pharyngitis, epiglottitis, laryngitis, laryngotracheitis, tracheitis, and combinations thereof.

### Claim 5 (depends on 1)

The method in accordance with claim 1, wherein the heat treatment is performed at a temperature from 120-140° C. for 5-15 seconds.

### Claim 6 (depends on 1)

The method in accordance with claim 1 comprising the step of reducing the time the upper respiratory tract infection will last.

### Claim 7 (depends on 1)

The method in accordance with claim 1 comprising the step of helping children to get upper respiratory tract infections less often.

### Claim 8 (depends on 1)

The method in accordance with claim 1, wherein the composition comprises the non replicating probiotic micro-organisms in an amount corresponding to about 106 to 1012 cfu.

### Claim 9 (depends on 1)

The method in accordance with claim 1, wherein the composition contains about 0.005 mg-1000 mg non-replicating micro-organisms per daily dose.

### Claim 10 (depends on 1)

The method in accordance with claim 1, wherein the individual has a symptom selected from the group consisting of cough, sore throat, runny nose, nasal congestion, headache, low grade fever, facial pressure, sneezing, and combinations thereof.

### Claim 11 (depends on 1)

The method in accordance with claim 1, wherein the probiotic micro-organisms are selected from the group consisting of Bifidobacterium longum BB536 (ATCC BAA-999), Lactobacillus casei CTP31 (NCC 4006), and a combination thereof.

### Claim 12

A method for treatment of an upper respiratory tract infection, the method comprising:
administering to an individual in need of same a composition comprising non-replicating probiotic micro-organisms that have been rendered non-replicating by a heat treatment performed at a temperature from 120-140° C. for 5-15 seconds, and the non-replicating probiotic micro-organisms are selected from the group consisting of Bifidobacteria, Lactobacilli, Propionibacteria, and combinations thereof.

### Claim 13 (depends on 12)

The method in accordance with claim 12, wherein the upper respiratory tract infection is selected from the group consisting of rhinitis, rhinosinusitis, nasopharyngitis, pharyngitis, epiglottitis, laryngitis, laryngotracheitis, tracheitis, and combinations thereof.

### Claim 14 (depends on 12)

The method in accordance with claim 12, wherein the composition comprises the non replicating probiotic micro-organisms in an amount corresponding to about 106 to 1012 cfu.

### Claim 15 (depends on 12)

The method in accordance with claim 12, wherein the composition contains about 0.005 mg-1000 mg non-replicating micro-organisms per daily dose.

### Claim 16 (depends on 12)

The method in accordance with claim 12, wherein the individual has a symptom selected from the group consisting of cough, sore throat, runny nose, nasal congestion, headache, low grade fever, facial pressure, sneezing, and combinations thereof.

### Claim 17

A method for treatment of an upper respiratory tract infection, the method comprising:
administering to an individual in need of same a composition comprising non-replicating probiotic micro-organisms that have been rendered non-replicating by a heat-treatment at 120-140° C. for about 1-120 seconds, wherein the composition comprises probiotics, and at least 90% of the probiotics are the non-replicating probiotic micro-organisms.

### Claim 18 (depends on 17)

The method in accordance with claim 17, wherein the upper respiratory tract infection is selected from the group consisting of rhinitis, rhinosinusitis, nasopharyngitis, pharyngitis, epiglottitis, laryngitis, laryngotracheitis, tracheitis, and combinations thereof.

### Claim 19 (depends on 17)

The method in accordance with claim 17, wherein the heat treatment is performed at a temperature from 120-140° C. for 5-15 seconds.

### Claim 20 (depends on 17)

The method in accordance with claim 17, wherein the composition comprises the non replicating probiotic micro-organisms in an amount corresponding to about 106 to 1012 cfu.

### Claim 21 (depends on 17)

The method in accordance with claim 17, wherein the composition contains about 0.005 mg-1000 mg non-replicating micro-organisms per daily dose.

### Claim 22 (depends on 17)

The method in accordance with claim 17, wherein the individual has a symptom selected from the group consisting of cough, sore throat, runny nose, nasal congestion, headache, low grade fever, facial pressure, sneezing, and combinations thereof.
